Deepnoid딥노이드

Deepnoid's shares have fallen sharply over the year while losses remain deep and revenue has shrunk.

Deepnoid, a Korean medical and industrial AI developer listed on KOSDAQ, reported trailing twelve-month revenue of ₩4.5B against an operating loss of ₩14.0B as of H1 2026. Its share price closed at ₩1,799 on 2026-10-23, down 60.1% over one year, with a market capitalisation of about ₩52.8B. The filings and news in the pack centre on medical AI product expansion and a series of 5%+ holding reports.

What stands out

• Trailing revenue of ₩4.5B is well below 2024's ₩10.8B and 2025's ₩7.5B, with 2025 revenue down 31.1% year on year.
• Operating margin is -311.3% and net margin is -317.8% on a trailing basis, so losses are large relative to sales.
• Free cash flow is negative at about -₩11.8B, and borrowings of ₩6.7B exceed cash of ₩4.4B.
• Price-to-book is 2.5 and price-to-sales is 11.7; price-to-earnings is not meaningful because earnings are negative.
• Foreign ownership fell from 4.4% to 2.4% over 60 days, and the 20-day flows show retail and institutional net selling against small foreign net buying.

What to watch

• The next periodic results and any update to the H1 2026 losses and cash position, which the data does not yet cover.
• Further 5%+ holding reports, which have appeared frequently in 2026 filings.
• Whether the newly announced medical AI studies and cancer diagnosis expansion translate into reported revenue; the data gives no forecasts for this.